Maximus review

A low dose is an advertised product here rather than something you quietly under-fill, and it names the starting dose against each price — a quarter of a milligram a week for semaglutide, one and a half for tirzepatide. That anchors the figure to an actual amount of drug, which most providers here do not do, and it states in its own words that compounded medications are not FDA-approved and are prepared by licensed 503A/503B pharmacies. The gap is what surrounds the number. Both prices print a bare per-month suffix with no plan length, no billing cadence and no statement of whether the rate requires a commitment, anywhere on the page. In this category an unqualified monthly figure is often a prepay rung rather than a standing rate, and nothing on this page tells you which this one is. So the dose is trustworthy here and the period is not, and the two are usually the other way round. Maximus also carries an FDA warning letter, which we disclose rather than treat as disqualifying — and it is a men's hormone brand, so the GLP-1 sits inside a protocol built around a particular patient.

Vs median

$76/mo below the $175 median across the 299 of 548 programs here that publish a plain monthly rate

Market

$59–$1,300/mo is the full published spread on this site

Structure

Charges less for less

Consult

Included in the price

Dietitian

Not confirmed

Labs

Not required

Pricing

Check plan terms

Maximus says it uses a 503A pharmacy, but does not say which one. No bloodwork is required before you start. A clinician review is included in the price.

Maximus is a men's telehealth brand — testosterone and hormone protocols — that runs a dedicated GLP-1 microdosing page presenting a low-dose protocol as its own product. The page names the starting dose against each price, which is more than most providers here do, and states plainly that compounded medications are not FDA-approved and are prepared by licensed 503A/503B pharmacies.

THE "/mo" HAS NO PERIOD ATTACHED. Neither price on the microdosing page states a plan length, a billing cadence or whether the rate requires a commitment — and this site has repeatedly found that an unqualified "/mo" in this category is a prepay rung rather than a standing rate. Treat both figures as unverified monthly rates until Maximus says what they buy

• FDA warning letter 730095 (June 2026) to Maximus Health, Inc. dba Maximus, for false and misleading claims and misbranding in telehealth marketing. It is disclosed here; a letter is a disclosure, not a disqualification
• It is a men's hormone brand, so a reader who is not its target patient is buying inside a protocol built around someone else
• No compounding pharmacy is named — the page states the designation and not the identity
• Compounded GLP-1s are not FDA-approved, and intentional microdosing is off-label and unproven

Maximus is one of 548 low-dose GLP-1 programs compared on this site, and 299 of them publish a monthly rate you can read before signing up. The full list puts every published price in one place, with the companies that pay us listed first — something we state there, on the page it applies to.

Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.

• What the evidence actually shows
• What microdosing GLP-1 costs
• Is compounded GLP-1 safe?
• Microdose & reconstitution calculator
• The true annual cost of a plan